The Pharmaceutical Managers Institute

thepmi.com

The PMI is a professional membership organisation dedicated to the continuous learning, development and support of those working in management within the pharmaceutical industry. Our membership is diverse, covering Commercial, Marketing, Market Access, Product Management and Regulatory roles; representating over 80 pharmaceutical organisations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

USANA LAUNCHES NEW, CUTTING-EDGE MOOD AND RELAXATION PRODUCT LINE AT AMERICAS AND EUROPE VIRTUAL CONVENTION

Prnewswire | August 18, 2020

news image

Managing occasional stress and keeping a calm mind are vital for navigating today's world. And USANA's new Mood and Relaxation product line is designed to help. The company's annual Americas and Europe Convention went virtual this year, and USANA continued to impress with the launch of its new Stress Relief mood-support supplement and Calm Response essential oil balm. These products take a natural and mindful approach to overall health and well-being.* To find out more about USANA an...

Read More

Business Insights, PHARMA TECH

LYRA COMPLETES ENROLLMENT IN LYR-220 BEACON PHASE 2 CLINICAL TRIAL

Lyra Therapeutics | February 08, 2023

news image

On February 6, 2023, Lyra Therapeutics, Inc., a leading clinical-stage biotechnology firm developing novel therapies for the localized treatment of chronic rhinosinusitis (CRS), announced that enrollment in the Phase 2 BEACON clinical trial of LYR-220 in adult patients with CRS who have previously undergone sinus surgery has been completed. LYR-220 is designed to provide continuous anti-inflammatory medicine (mometasone furoate; MF) to the sinonasal passageways for six months in...

Read More

Business Insights

THERAPEUTICSMD AND EW HEALTHCARE PARTNERS ANNOUNCE DEFINITIVE AGREEMENT FOR EW HEALTHCARE PARTNERS TO ACQUIRE THERAPEUTICSMD

TherapeuticsMD, Inc | June 01, 2022

news image

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding sh...

Read More

Business Insights

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

news image

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More
news image

USANA LAUNCHES NEW, CUTTING-EDGE MOOD AND RELAXATION PRODUCT LINE AT AMERICAS AND EUROPE VIRTUAL CONVENTION

Prnewswire | August 18, 2020

Managing occasional stress and keeping a calm mind are vital for navigating today's world. And USANA's new Mood and Relaxation product line is designed to help. The company's annual Americas and Europe Convention went virtual this year, and USANA continued to impress with the launch of its new Stress Relief mood-support supplement and Calm Response essential oil balm. These products take a natural and mindful approach to overall health and well-being.* To find out more about USANA an...

Read More
news image

Business Insights, PHARMA TECH

LYRA COMPLETES ENROLLMENT IN LYR-220 BEACON PHASE 2 CLINICAL TRIAL

Lyra Therapeutics | February 08, 2023

On February 6, 2023, Lyra Therapeutics, Inc., a leading clinical-stage biotechnology firm developing novel therapies for the localized treatment of chronic rhinosinusitis (CRS), announced that enrollment in the Phase 2 BEACON clinical trial of LYR-220 in adult patients with CRS who have previously undergone sinus surgery has been completed. LYR-220 is designed to provide continuous anti-inflammatory medicine (mometasone furoate; MF) to the sinonasal passageways for six months in...

Read More
news image

Business Insights

THERAPEUTICSMD AND EW HEALTHCARE PARTNERS ANNOUNCE DEFINITIVE AGREEMENT FOR EW HEALTHCARE PARTNERS TO ACQUIRE THERAPEUTICSMD

TherapeuticsMD, Inc | June 01, 2022

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding sh...

Read More
news image

Business Insights

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us